Cancers, Volume 15, Issue 7
2023 April-1 - 271 articles
Cover Story: Treatment options after progression on CDK4/6 inhibitors are limited. Recent trials have reported encouraging efficacy of novel drugs such as the AKT inhibitors (Capivasertib), oral selective estrogen receptor degraders such as Elacestrant, proteolysis targeting chimeras (PROTACs) and PARP inhibitors. Some patients may benefit from the continuation of CDK4/6 inhibitors beyond progression. However, the efficacy of these treatments remains modest. In this narrative review, we take a deep dive into the data supporting these new treatments and discuss existing evidence gaps, limitations, and ongoing clinical trials. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.